Secondary interstitial lung disease specific to childhood associated with a systemic disease

Secondary interstitial lung disease specific to childhood associated with a systemic disease (Orphanet code 264699) is a category of childhood interstitial lung diseases (chILD) in which the lung involvement occurs as a secondary manifestation of an underlying systemic condition. Systemic diseases that can lead to this form of interstitial lung disease in children include connective tissue disorders (such as juvenile dermatomyositis, systemic lupus erythematosus, and systemic sclerosis), vasculitis syndromes, sarcoidosis, storage diseases (such as Gaucher disease and Niemann-Pick disease), and other multisystem inflammatory or metabolic conditions. The lungs are the primary organ affected in this subcategory, but because the disease arises in the context of a systemic disorder, other organ systems — including the skin, joints, kidneys, liver, and hematopoietic system — may also be involved depending on the underlying condition. Key pulmonary symptoms include chronic cough, progressive dyspnea (difficulty breathing), tachypnea (rapid breathing), exercise intolerance, and in some cases hypoxemia (low blood oxygen levels). Chest imaging typically reveals diffuse interstitial changes such as ground-glass opacities, reticular patterns, or consolidation. Pulmonary function testing, when feasible in older children, may show restrictive patterns with reduced diffusion capacity. Failure to thrive and recurrent respiratory infections may also be prominent features, particularly in younger children. Treatment is directed at managing the underlying systemic disease and controlling pulmonary inflammation. This often involves immunosuppressive or immunomodulatory therapies such as corticosteroids, methotrexate, azathioprine, mycophenolate mofetil, or biologic agents, depending on the specific systemic diagnosis. Supportive care including supplemental oxygen, pulmonary rehabilitation, and nutritional support may be necessary. Prognosis varies widely depending on the underlying systemic condition, the severity of lung involvement, and the response to treatment. Early recognition and multidisciplinary management involving pulmonologists, rheumatologists, and other specialists are essential for optimizing outcomes in affected children.

Common questions about Secondary interstitial lung disease specific to childhood associated with a systemic disease